Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01344837 · ClinicalTrials.gov registry record
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
A clinical trial of Endometrial Serous Adenocarcinoma and Stage I Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- 360
- Enrollment target
- 1
- Study location
NCT01344837: Completed study of Endometrial Serous Adenocarcinoma and Stage I Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group.
NCT01344837 is a study of Endometrial Serous Adenocarcinoma and Stage I Uterine Corpus Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 360 participants, above the 272-participant average among 12 other Endometrial Serous Adenocarcinoma trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01344837, a study of Endometrial Serous Adenocarcinoma and Stage I Uterine Corpus Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- 360 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying biomarkers in blood and tissue samples from patients with uterine cancer. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.
Primary Outcome
Kaplan-Meier survival curves for the overall survival (OS) endpoint will be generated separately for the three SNCG expression groups and globally compared using a log-rank test.
Conditions Studied
Interventions
- OTHER Medical Chart Review
- OTHER Diagnostic Laboratory Biomarker Analysis
- OTHER Study of Socioeconomic and Demographic Variables
- OTHER Immunohistochemistry Staining Method
- GENETIC Microarray Analysis
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2010-01 |
| Est. Completion | 2018-01 |
What the finished NCT01344837 record still lists
NCT01344837 is an observational study that tracks outcomes without assigning an intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 272-participant average among 12 other Endometrial Serous Adenocarcinoma trials with a reported enrollment target (32% higher).
The record links to 5 conditions, with Endometrial Serous Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Medical Chart Review is the first listed.
NCT01344837 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01344837 about?
NCT01344837 is a clinical study titled "Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer". This research study is studying biomarkers in blood and tissue samples from patients with uterine cancer. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.
What is the current status of trial NCT01344837?
This trial is currently completed. The enrollment target is 360 participants. The study started on 2010-01. Estimated completion is 2018-01.
What conditions does trial NCT01344837 study?
This clinical trial studies the following conditions: Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer.
What interventions are being tested in trial NCT01344837?
The interventions under investigation include: Medical Chart Review (OTHER), Diagnostic Laboratory Biomarker Analysis (OTHER), Study of Socioeconomic and Demographic Variables (OTHER), Immunohistochemistry Staining Method (OTHER), Microarray Analysis (GENETIC).
Who is sponsoring clinical trial NCT01344837?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01344837 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Serous Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01344837's enrollment target sits among peer trials
360 3rd of 12 higher than 9 of 12 other Endometrial Serous Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Serous Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RECRUITING · Phase 3
-
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
RECRUITING · Phase 3
-
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
RECRUITING
-
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
ACTIVE NOT RECRUITING · NA
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia